Safety and Efficacy Study of Etanercept (Qiangke®) to Treat Moderate to Severe Plaque Psoriasis
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, multicentral clinical trial to investigate the efficacy
and safety of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection (Qiangke®) in
the treatment of Moderate to Severe Plaque Psoriasis. The primary purpose is to assess the
different maintaining treatment programme in Moderate to Severe plaque psoriasis by Qiangke®.
And the second purpose is to assess the efficacy and safety of Qiangke® in Moderate to Severe
Plaque Psoriasis. The trial will include 216 Moderate to Severe plaque psoriasis patients,and
at the first stage they will be randomized divided into three group: full-dose of Qiangke®
group, half-dose of Qiangke® group and placebo group.And the blind stage will last for 12
weeks. Then at the second stage, all patients will receive 50mg qw of Qiangke® for additional
12 weeks.